Si-bone, Inc. · NASDAQ:SIBN
Si-bone — Investor Presentation (January 2026)
26 slides from Si-bone's investor presentation, Jan 12, 2026
Slide 1: SI-BONE Corporate Overview January 2026
SI-BONE Corporate Overview January 2026
Slide 2: Forward-Looking Statements
The statements in this presentation regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, are “forward-looking” statements. These forward-looking statements are based on SI-BONE’s current expectations and
Slide 3: Financial Update
Financial Update
Slide 4: Key Highlights – Record Performance Fourth Quarter 2025
Key Highlights – Record Performance 4 Fourth Quarter 2025 • ~15% worldwide revenue growth: $56.2 to $56.3 million • ~14% U.S. revenue growth: $53.3 to $53.4 million • ~18% growth in U.S. active physicians Fiscal Year 2025 • ~20% worldwide revenue growth: $200.8 to $200.9 million • ~21% U.S. revenue
Slide 5: Strong Demand Drove Record Revenue in 2025
WW REVENUE ($M) Strong Demand Drove Record Revenue in 2025 5 2025 WW REVENUE ($M) 2025 U.S. Revenue ($M) Note: As of December 31, 2025 Note: The fourth quarter and full year 2025 revenue and cash and equivalents are included on a preliminary basis, prior to the completion of SI-BONE's financial clos
Slide 6: Record Physician Engagement Driving Procedure Demand
Record Physician Engagement Driving Procedure Demand 6 U.S. ACTIVE PHYSICIAN BASE 1,390 4Q24 4Q25 ~18% 5 consecutive years of double-digit U.S. active physician growth every quarter Broad-based volume growth across all procedure types Note: As of December 31, 2025 Note: Rounded for presentation purp
Slide 7: Platform Set-up to Deliver Strong Revenue Growth and Operating Leverage
Commercial Execution Accelerate market expansion Physician Engagement Drive penetration and adoption Innovation Build differentiated portfolio Long-Term Business Drivers Platform Set-up to Deliver Strong Revenue Growth and Operating Leverage 7 Operational Excellence Expand Profitability Expand sales
Slide 8: Differentiated Portfolio Complemented By Strong Fundamentals
8 Differentiated Portfolio Complemented By Strong Fundamentals Robust Data Reimbursement Advantage Strong Execution Track Record Large, Underpenetrated Markets 200+ published papers 4 Randomized Controlled Trials TPT for iFuse Bedrock Granite NTAP for iFuse TORQ TNT 5 Years of double-digit U.S. acti
Slide 9: Company Overview
Company Overview
Slide 10: Market Leading Platform For Compromised Bone Procedural Solutions
Market Leading Platform For Compromised Bone Procedural Solutions Innovation 3 Breakthrough Designated Devices 72 WW Patents Evidence 4 Randomized Controlled Trials 1,2 200+ Peer-reviewed Publications 3 Education ~1,640 Active US Physicians 5,6 140,000+ Procedures Performed 7 Commercialization 89 Te
Slide 11: Large Addressable Markets with Attractive Fundamentals
Large Addressable Markets with Attractive Fundamentals ~470,000 Target U.S. Annual Procedures 1 > $3.5 Billion Total U.S. Addressable Market 1 280,000 60,000 130,000 SI Joint Dysfunction 2 Pelvic Trauma 5 Sacropelvic Fixation Adult Deformity 3 + Degenerative Spine 4 $2.4 Billion $0.3 Billion $1.0 Bi
Slide 12: Three Large Unmet Clinical Needs In Sacropelvic Conditions
Three Large Unmet Clinical Needs In Sacropelvic Conditions 12 Pelvic Trauma Sacropelvic Fixation 24% Rate of Failure ASD Surgery 5 28% SI Joint Issues Post Spinal Fusion 6 SI Joint Dysfunction 15-30% Chronic LBP is SI Joint 1 High Burden of Disease 2 27% Mortality from Bedrest, Downward Spiral 3 14-
Slide 13: Innovation Driven Differentiated Platform
Innovation Driven Differentiated Platform iFuse 3D iFuse Market Leader in SI Joint Fusion iFuse TORQ® iFuse TORQ TNT Cutting-Edge Pelvic Fixation & Fusion; and Fragility Fractures Sacropelvic Fixation iFuse Bedrock Granite® Breakthrough Fixation, Fusion, Foundation 13 Higher pull-out strength vs. So
Slide 14: Patent Protected Differentiated Platform
Patent Protected Differentiated Platform ▪ 72 issued patents: U.S. (49), OUS (23) ▪ iFuse 3D implant patents until Sept 2035 ▪ Triangular broach instrument patent until Feb 2034 ▪ iFuse implant patent until May 2026 3-D TECHNOLOGY Rectilinear profile, longitudinal struts, and struts connecting the l
Slide 15: Portfolio Overview
Portfolio Overview
Slide 16: Sacroiliac Joint Dysfunction Treatments
Procedures Non-surgical Management Sacroiliac Joint Dysfunction Treatments 16 MIS SI Joint Fusion Radiofrequency Ablation Therapeutic SI Joint Injections (anesthetic & steroids) External Support (SI Joint Belt) Physical Therapy Medications (NSAIDS, opiates, etc.) Bone Allograft SI Joint Stabilizatio
Slide 17: Proprietary, Differentiated iFuse Technology
Proprietary, Differentiated iFuse Technology® Rotation 6x resistance (vs. 12mm Rialto screw)1 Strength 3x strength (vs. stand 8.0mm cannulated screw)2 Safety Low complication rate3,4 Revision 3.5% (4-year)5 Clinical Evidence 2 RCTs6 Surface Porous 1. SI-BONE Technical Study 300610-TS. To
Slide 18: SALLY Prospective Clinical Trial: iFuse 3D 5-year Outcomes
18 SALLY Prospective Clinical Trial: iFuse 3D 5-year Outcomes1 Rapid, marked and durable improvements in pain, patient function and quality of life Equivalence to iFuse 2 ✓ Demonstrated Objective Functional Improvement 3 Accelerated SI Joint Fusion 1,4 ✓ Important improvement ✓ 100% bone integration
Slide 19: iFuse TORQ: Cutting-Edge Pelvic Fixation and Fusion
Large, Adjacent Market 1 Differentiated Technology Competitive Advantages >$300 million Pelvic Trauma opportunity ~120K Sacral Fragility fracture incidence / yr. FuSIon 3D Surface for Osseointegration IntelliHarvest® Technology self harvests host bone TORQLock Threads2 10x rotational resistance on i
Slide 20: iFuse TORQ TNT: Pelvic Bone Density-Driven Design
• Through ‘N Through (“TNT”)1 • FDA Breakthrough Device Designation2 • Pelvic fragility fracture fixation • Pelvic-specific 8.7mm diameter • 3D-printed porous lattice surface designed for osseointegration 20 iFuse TORQ TNT : Pelvic Bone Density-Driven Design 1. The first 3D-printed, porous threaded
Slide 21: iFuse Bedrock Granite: Fixation. Fusion. Foundation.
21 iFuse Bedrock Granite®: Fixation. Fusion. Foundation. Large, Adjacent Market ~$1 billion Adult Spinal Deformity and Degenerative Spine pelvic fixation opportunity1 Competitive Advantages Breakthrough Device Designation by the FDA Proposed extension of Transitional Pass-Through (TPT) Payment statu
Slide 22: iFuse Bedrock Granite – 9.5mm Diameter Implant
• Line extension of our breakthrough implant • Smaller diameter (9.5mm) • 3D-printed lattice & surface technology • Additional application for use in S1 trajectory and pediatric deformity1 22 iFuse Bedrock Granite® – 9.5mm Diameter Implant 1. 510(k) Clearance – K233508 (Jan 2024) FDA Clearance Janua
Slide 23: Disclosure: iFuse Bedrock Granite Indications
Disclosure The iFuse Bedrock Granite® Implant System is intended for sacroiliac joint fusion in skeletally mature patients for the following conditions: • Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whos
Slide 24: Disclosure: iFuse TORQ Indications
Disclosure The iFuse TORQ® Implant System is indicated for: • Fusion of the sacroiliac joint for sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis. • Fracture fixation of the pelvis, including acute, non-acute and non-traumatic fractures. The iFuse TORQ
Slide 25: Disclosure: iFuse Implant System Indications
Disclosure The iFuse Implant System® is intended for sacroiliac fusion for the following conditions: • Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartu
Slide 26: Pioneering Procedural Solutions For Compromised Bone
1/10/2026 h Pioneering Procedural Solutions For Compromised Bone ® 26 140,000+ Procedures 72+ Patents 200+ Publications Note: As of December 31, 2025